المؤلفون: Shi, Mai, Liu, Zhao-lan, Zhu, Yan-bo, Xu, Mei-yan, Duan, Xue-ying, Shi, Hui-mei, Jiang, Bo, Zhang, Xiao-mei, Yu, Xiao-han

المصدر: Chinese Journal of Integrative Medicine; Feb2018, Vol. 24 Issue 2, p94-102, 9p

مصطلحات موضوعية: TYPE 2 diabetes treatment, HEALTH education evaluation, TREATMENT effectiveness, GLYCOSYLATED hemoglobin, MEDICINE, CHINESE medicine, QUALITY of life, REGRESSION analysis, STATISTICAL sampling, T-test (Statistics), TIME, INTEGRATIVE medicine, BODY mass index, RANDOMIZED controlled trials, CONTROL groups, DATA analysis software, DESCRIPTIVE statistics, ADULTS

مستخلص: Objective: To investigate the effects of health education based on integrative therapy of Chinese and Western medicine for type 2 diabetes mellitus (T2DM) from the aspects of knowledge, attitude and practice (KAP), health-related quality of life (HRQoL), body mass index (BMI) and glucose control. Methods: Patients were individually randomized into intervention group (receiving integrative education, n=120) and control group (receiving usual education, n=120). The primary outcome was the changes in glycosylated hemoglobin A1c (HbA1c) levels after 3, 6, 9 and 12 months from baseline. Hierarchical linear models (HLMs) were used to assess within-group changes in outcomes over time and between-group differences in patterns of change. Secondary outcomes were KAP scores, HRQoL scores and BMI after 6 and 12 months, paired-sample t test was used to assess within-group changes in outcomes in 6 and 12 months, independent-sample t test was used to assess between-group differences in patterns of change. Results: HbA1c decreased statistically from baseline to 3 months, from 3 to 6 months, from 6 to 9 months and from 9 to 12 months in the intervention group (all P<0.01); and decreased significantly from baseline to 3 months, and from 3 to 6 months in the control group P<0.01). There was a significant between-group difference from baseline to 3 months ( P=0.044), from 6 to 9 months ( P<0.01) and from 9 to 12 months ( P<0.01). Significant improvements in the intervention group along with significant between-group differences were found in KAP and HRQoL scores respectively (all P<0.05). The number in the intervention group of normal weight increased from 56 at baseline to 81 (6 months), 94 (12 months), the number in the control group were 63 (baseline), 69 (6 months), 70 (12 months), the χ of hierarchical analysis of BMI were 6.93 ( P=0.075), 10.31 ( P=0.016), 15.53 ( P<0.01), respectively. Conclusion: Health education based on integrative therapy of Chinese and Western medicine is beneficial to the control of T2DM and should be recommended for T2DM. [ABSTRACT FROM AUTHOR]

: Copyright of Chinese Journal of Integrative Medicine is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Deng, Bo, Jia, Li-qun, Wan, Dong-gui, Wang, Bao-yi, Cheng, Zhi-qiang, Deng, Chao

المصدر: Chinese Journal of Integrative Medicine; Jul2022, Vol. 28 Issue 7, p579-585, 7p

مصطلحات موضوعية: DRUG efficacy, PERIPHERAL neuropathy, HERBAL medicine, VITAMIN B12, CANCER chemotherapy, FUNCTIONAL status, QUANTITATIVE research, RANDOMIZED controlled trials, PLACEBOS, BLIND experiment, QUALITY of life, DESCRIPTIVE statistics, QUESTIONNAIRES, DRUG side effects, DATA analysis software, CHINESE medicine, DRUG administration, DRUG dosage

الشركة/الكيان: NATIONAL Cancer Institute (U.S.)

مستخلص: Objective: To evaluate the efficacy of Wen-Luo-Tong Granules (WLT) local administration in the treatment of patients with peripheral neuropathy (PN) induced by chemotherapy or target therapy. Methods: This study is a randomized, double-blinded, and placebo-controlled trial. Seventy-eight patients with PN induced by chemotherapy or target therapy were enrolled from China-Japan Friendship Hospital between July 2019 and January 2020. They were randomly assigned to WLT (39 cases) and control groups (39 cases) using a block randomization method. The WLT group received WLT (hand and foot bath) plus oral Mecobalamin for 1 week, while the control group received placebo plus oral Mecobalamin. The primary endpoint was PN grade evaluated by the National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE). The secondary endpoints included quantitative touch-detection threshold, neuropathy symptoms, Quality of Life Questionnaire-Chemotherapy Induced Peripheral Neuropathy (QLQ-CIPN20), and Quality of Life Questionnaire-Core30 (QLQ-C30). Results: After treatment, the PN grade in the WLT group was significantly lower than that in the control group (1.00 ± 0.29 vs. 1.75 ± 0.68, P<0.01). The total effective rate in the WLT group was significantly higher than that in the control group (82.05% vs. 51.28%, P<0.01). Compared with the control group, the touch-detection thresholds at fingertips, neuropathy symptom score, QLQ-CIPN 20 (sensory scale, motor scale, autonomic scale, and sum score), and QLQ-C30 (physical functioning, role functioning, emotional functioning, and global health) in the WLT group significantly improved after treatment (P<0.01 or P<0.05). Conclusion: WLT local administration was significantly effective in the treatment of patients with PN induced by chemotherapy or target therapy. (Trial registration No. ChiCTR1900023862) [ABSTRACT FROM AUTHOR]

: Copyright of Chinese Journal of Integrative Medicine is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Huang, Yuan-peng, Wen, Yan-hui, Wu, Geng-hui, Hong, Zhen-feng, Xu, Shang-wen, Peng, A-xiang

المصدر: Chinese Journal of Integrative Medicine; Dec2014, Vol. 20 Issue 12, p949-954, 6p

مصطلحات موضوعية: CHINESE medicine, COMBINATION drug therapy, CHI-squared test, HERBAL medicine, QUALITY of life, RESEARCH funding, T-test (Statistics), URODYNAMICS, BENIGN prostatic hyperplasia, RANDOMIZED controlled trials, TREATMENT effectiveness, DATA analysis software, DESCRIPTIVE statistics, THERAPEUTICS

مصطلحات جغرافية: CHINA

مستخلص: Objective: To observe the effectiveness and safety of Kangquan Recipe (康泉方, KQR) for benign prostatic hyperplasia (BPH) patients. Methods: One hundred and six BPH patients were randomly assigned to the treatment group (53 cases) and the control group (53 cases) according to a random number table. The treatment group was given KQR orally; the control group was given cernilton orally. After 24-week treatment, the clinical effect and safety were evaluated using the International Prostatic Symptom Score (I-PSS), quality of life (QOL), maximum flow rate (Qmax), average flow rate (Qave), residual urine volume (RUV), total prostatic volume (TPV), etc. Results: After treatment, the score of I-PSS was decreased from 16.9±5.6 to 12.5±4.6 in the treatment group, significantly lower compared with the control group; the levels of Qmax and Qave were from 10.9±3.5 to 15.6±4.5 and 5.4±2.1 to 7.3±2.5 (mL/s) in the treatment group, significantly higher compared with the control group; the levels of RUV and TPV were from 70.8±28.2 to 35.2±21.8 and 37.2±16.9 to 30.1±10.8 (mL) in the treatment group, significantly lower compared with the control group (all P<0.05). The incidence rate of adverse reaction was similar between the two groups ( P>0.05). Conclusion: KQR is effective and safe for the treatment of BPH. [ABSTRACT FROM AUTHOR]

: Copyright of Chinese Journal of Integrative Medicine is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Zhang, Shao-yan, Qiu, Lei, Zhang, Shun-xian, Xiao, He-ping, Chu, Nai-hui, Zhang, Xia, Zhang, Hui-qiang, Zheng, Pei-yong, Zhang, Hui-yong, Lu, Zhen-hui

المصدر: Chinese Journal of Integrative Medicine; Jul2024, Vol. 30 Issue 7, p579-587, 9p

مصطلحات موضوعية: DRUG therapy for tuberculosis, CHINESE medicine, PATIENT safety, PLACEBOS, RESEARCH funding, HERBAL medicine, STATISTICAL sampling, BLIND experiment, QUESTIONNAIRES, FUNCTIONAL assessment, RANDOMIZED controlled trials, HOSPITALS, SPUTUM, DESCRIPTIVE statistics, FUNCTIONAL status, ADJUVANT chemotherapy, DRUG efficacy, RESEARCH, QUALITY of life, ALTERNATIVE medicine, COMPARATIVE studies, PATIENT monitoring, DRUG dosage, THERAPEUTICS, EVALUATION, DRUG administration

مصطلحات جغرافية: CHINA

مستخلص: Objective: To assess the efficacy and safety of Bufei Jiedu (BFJD) ranules as adjuvant therapy for patients with multidrug-resistant pulmonary tuberculosis (MDR-PTB). Methods: A large-scale, multi-center, double-blinded, and randomized controlled trial was conducted in 18 sentinel hospitals in China from December 2012 to December 2016. A total of 312 MDR-PTB patients were randomly assigned to BFJD Granules or placebo groups (1:1) using a stratified randomization method, which both received the long-course chemotherapy regimen for 18 months (6 Am-Lfx-P-Z-Pto, 12 Lfx-P-Z-Pto). Meanwhile, patients in both groups also received BFJD Granules or placebo twice a day for a total of 18 months, respectively. The primary outcome was cure rate. The secondary outcomes included time to sputum-culture conversion, changes in lung cavities and quality of life (QoL) of patients. Adverse reactions were monitored during and after the trial. Results: A total of 216 cases completed the trial, 111 in the BFJD Granules group and 105 in the placebo group. BFJD Granules, as an adjuvant treatment, increased the cure rate by 13.6% at the end of treatment, compared with the placebo (58.4% vs. 44.8%, P=0.02), and accelerated the median time to sputum-culture conversion (5 months vs. 11 months). The cavity closure rate of the BFJD Granules group (50.6%, 43/85) was higher than that of the placebo group (32.1%, 26/81; P=0.02) in patients who completed the treatment. At the end of the intensive treatment, according to the 36-item Short Form, the BFJD Granules significantly improved physical functioning, general health, and vitality of patients relative to the placebo group (all P<0.01). Overall, the death rates in the two groups were not significantly different; 5.1% (8/156) in the BFJD Granules group and 2.6% (4/156) in the placebo group. Conclusions: Supplementing BFJD Granules with the long-course chemotherapy regimen significantly increased the cure rate and cavity closure rates, and rapidly improved QoL of patients with MDR-PTB (Registration No. ChiCTR-TRC-12002850) [ABSTRACT FROM AUTHOR]

: Copyright of Chinese Journal of Integrative Medicine is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Wu, Shi-hao, Shi, Wei-qi, Li, Yu-hang, Liu, Ru-hui, Hu, Da-yi, Zheng, Li-qiang, Ma, Wen-lin

المصدر: Chinese Journal of Integrative Medicine; May2024, Vol. 30 Issue 5, p443-448, 6p

مصطلحات موضوعية: CHINESE medicine, ANGINA pectoris, CORONARY disease, HERBAL medicine, QUESTIONNAIRES, FUNCTIONAL assessment, ANXIETY, DESCRIPTIVE statistics, FUNCTIONAL status, DRUG efficacy, QUALITY of life, COMPARATIVE studies, PATIENT satisfaction, PUBLIC health, MENTAL depression, COMORBIDITY, THERAPEUTICS, EVALUATION, DISEASE complications

مستخلص: Objective: To evaluate the efficacy of Guanxin Danshen Dripping Pill (GXDSDP) in treating anxiety and depression in patients with coronary heart disease (CHD). Methods: A total of 1,428 patients diagnosed with CHD screened for anxiety, depression, and quality of life (QOL) at baseline received 0.4 g of GXDSDP treatment 3 times per day and returned for monthly reassessment. Patients were recruited after stable treatment for CHD and received assessment of General Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9), and Seattle Angina Questionnaire (SAQ) for evaluating anxiety, depression, and QOL. Patients were followed up 3 times, once every 4 weeks, during outpatient visits for 12 weeks. Results: At the third follow-up (F3), the anxiety symptom of 63.79% (673/1,055) of the patients improved to sub-clinical level, and the GAD-7 score improved significantly (8.11 vs. 3.87, P<0.01); 57.52% (585/1,017) patients' depressive symptoms improved to sub-clinical level, with a significant improvement in PHQ-9 score (8.69 vs. 4.41, P<0.01) at F3. All aspects of QOL significantly improved at the end of treatment compared to those at baseline (all P<0.01) as assessed by SAQ: physical limitation (31.17 vs. 34.14), anginal stability (2.74 vs. 4.14), anginal frequency (8.16 vs. 9.10), treatment satisfaction (13.43 vs. 16.29), and disease perception (8.69 vs. 11.02). Conclusions: A fixed dosage of GXDSDP may be a potential treatment option for CHD patients comorbid with anxiety or depression. (Registration No. ChiCTR2100051523) [ABSTRACT FROM AUTHOR]

: Copyright of Chinese Journal of Integrative Medicine is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Liu, Si-pei, Zhou, Jian-guan, Jin, Yan, Guo, Yan, Zhou, Shi-wei, Lin, Mei-lan, Zhang, Jun, Wang, Xiao-nv, Guan, Xia-fei, Wang, Lei

المصدر: Chinese Journal of Integrative Medicine; Feb2023, Vol. 29 Issue 2, p99-107, 9p

مصطلحات موضوعية: HEART failure treatment, COMPETENCY assessment (Law), SLEEP quality, VENTRICULAR ejection fraction, HERBAL medicine, EXERCISE tolerance, OXYGEN consumption, HEALTH surveys, TREATMENT effectiveness, RANDOMIZED controlled trials, COMPARATIVE studies, PRE-tests & post-tests, BLIND experiment, RESEARCH funding, DESCRIPTIVE statistics, QUESTIONNAIRES, BODY movement, QUALITY of life, COMBINED modality therapy, STATISTICAL sampling, CHINESE medicine, EXERCISE therapy, ANAEROBIC threshold, THERAPEUTICS, EVALUATION

مستخلص: Objective: To evaluate the therapeutic efficacy of Shexiang Baoxin Pill combined with exercise in heart failure patients with preserved ejection fraction (HFpEF). Methods: Sixty patients with HFpEF were randomly divided into group A (n=20), receiving Shexiang Baoxin Pill combined with home-based exercise training based on conventional drugs for 12 weeks; group B (n=20), receiving conventional drugs combined with home-based exercise training for 12 weeks; and group C (n=20), receiving conventional drug treatment only. Peak oxygen uptake (peakVO2), anaerobic threshold (AT), 6-min walking test (6MWT), Pittsburgh Sleep Quality Index (PSQI), and SF-36 questionnaire (SF-36) results before and after treatment were compared among groups. Results: After the 12-week intervention, patients in group C showed significant declines in peakVO2, AT, 6MWT, PSQI, and SF-36 compared with pre-treatment (P<0.01), while groups A and B both showed significant improvements in peakVO2, AT, 6MWT, PSQI, and SF-36 results compared with pre-treatment (P<0.01). Compared with group C, patients in groups A and B showed significant improvements in peakVO2, AT, 6MWT, PSQI, and SF-36 (P<0.01). In addition, patients in group A showed more significant improvements in physical function, role-physical, vitality, and mental health scores on the SF-36 questionnaire, and PSQI scores than those in group B (P<0.01). Conclusions: Exercise training improved exercise tolerance, sleep quality and quality of life (QoL) in patients with HFpEF. Notably, Shexiang Baoxin Pill played an active role in sleep quality and QoL of patients with HFpEF. (The trial was registered in the Chinese Clinical Trial Registry (No. ChiCTR2100054322)) [ABSTRACT FROM AUTHOR]

: Copyright of Chinese Journal of Integrative Medicine is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Li, Xing-xing, Wu, Yang, Fan, Zong-jing, Cui, Jie, Li, Dong, Lin, Quan, Zhuang, Rui, Yan, Rong-kun, Lin, Qian, Li, Yan

المصدر: Chinese Journal of Integrative Medicine; Jan2022, Vol. 28 Issue 1, p12-19, 8p

مصطلحات موضوعية: HEART failure treatment, CHRONIC disease treatment, HEART physiology, HERBAL medicine, MANN Whitney U Test, RANDOMIZED controlled trials, T-test (Statistics), QUALITY of life, DESCRIPTIVE statistics, CHI-squared test, DATA analysis software, CHINESE medicine, LONGITUDINAL method

مصطلحات جغرافية: CHINA

مستخلص: Objective: To confirm the improvement of cardiac function and quality of life (QOL) in patients with chronic heart failure (CHF) via Chinese medicine (CM) Qishen Taohong Granule (芪参桃红颗粒, QTG). Methods: This study was a single-center, prospective, randomized, controlled clinical trial. Seventy-six patients from 27 to 84 years old diagnosed with CHF New York Heart Association (NYHA) class II or III in stage C were enrolled and randomly assigned at a 1:1 ratio to receive QTG or trimetazidine (TMZ), in addition to their standard medications for the treatment of CHF. The study period was 4 weeks. The primary outcomes included cardiac function evaluated by NYHA classification and left ventricular ejection fraction (LVEF), as well as QOL evaluated by CHF Integrated Chinese and Western Medicine Survival Scale (CHFQLS). The secondary outcomes included 6-min walking test (6MWT), CM syndrome score, symptom and sign scores and N-terminal pro-B-type natriuretic peptide (NT-proBNP). All indices were measured at baseline and the end of the trial. Results: At the 4-week follow-up period, the effective rate according to NYHA classification in the QTG group was better than that in the TMZ group (74.29% vs. 54.29%, P<0.05). But there was no significant difference in post-treatment level of LVEF between the two groups (P>0.05). The CHFQLS scores improved by 13.82±6.04 vs. 7.49±2.28 in the QTG and TMZ groups, respectively (P<0.05). Subgroup analysis of the CHFQLS results showed that physiological function, role limitation and vitality were significantly higher in the QTG group than in the TMZ group (15.76±7.85 vs. 7.40±3.36, P<0.05; 16.00±8.35 vs. 10.53±4.64, P<0.05; 15.31±8.09 vs. 7.89±4.60, P<0.05). Compared with TMZ group, treatment with QTG also demonstrated superior performance with respect to 6MWT, CM syndrome, shortness of breath, fatigue, gasping, general edema and NT-proBNP level. No significant adverse reactions or adverse cardiac events occurred during treatment in either group. Conclusion: In addition to conventional treatments, the use of QTG as an adjuvant therapy significantly improved cardiac function and QOL in patients with CHF class II or III in stage C. [Registration No. ChiCTR1900022036 (retrospectively registered)] [ABSTRACT FROM AUTHOR]

: Copyright of Chinese Journal of Integrative Medicine is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Wang, Yao-han, Chang, Jin-yuan, Feng, Li

المصدر: Chinese Journal of Integrative Medicine; Sep2021, Vol. 27 Issue 9, p713-720, 8p

مصطلحات موضوعية: MEDICINE, CANCER pain, ONLINE information services, META-analysis, MEDICAL information storage & retrieval systems, INFORMATION storage & retrieval systems, MEDICAL databases, CONFIDENCE intervals, ORAL drug administration, SYSTEMATIC reviews, ANALGESICS, DESCRIPTIVE statistics, QUALITY of life, COMBINED modality therapy, MEDLINE, CHINESE medicine, PAIN management

مصطلحات جغرافية: CHINA

مستخلص: Objective: To assess the effect of oral Chinese medicine (OCM) combined with Western medicine (WM) on cancer pain. Methods: PubMed, Embase, Cochrane Library, Clinical Trials Registry Platform, Chinese National Knowledge Infrastructure (CNKI), Wanfang and VIP databases were searched from their inception to September {dy2019}. Randomized controlled trials (RCTs) treating cancer pain by Chinese medicine (CM) combined with WM were included. The primary outcome were total pain relief rate and the quality of life (QOL), and the other outcomes were the average daily dosage of analgesics, the primary time of pain, the analgesic duration time, and adverse events. The methodological quality of RCTs was assessed in accordance with Cochrane 5.1.0 handbook of systematic reviews of interventions. Evidence level was assessed by the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach. Results: There were 1,087 patients in the 14 studies, with 544 in the experiment group and 543 in the control group. These studies were all conducted in China, and published between 2006 and {dy2019}. Compared with the WM, OCM combined with WM could significantly relieve the cancer pain [risk ratio (RR)=1.43, 95% confidence interval (CI): 1.32, 1.56), improve QOL (RR=8.57, 95% CI: 4.25, 12.89), decrease the primary time of pain (RR=−0.20, 95% CI: −0.24, −0.16], prolong the analgesic duration time (RR=3.47, 95% CI: 2.09, 4.85), reduce the dosage of analgesics (RR=−19.52, 95% CI: −36.32, −2.72), and reduce side events (RR=0.49, 95% CI: 0.37, 0.65). Evidence levels for total pain relief rate, primary time of pain and side events were low, evidence level for QOL, analgesic duration time and average daily dosage of analgesics were very low. Conclusions: Compared with the WM, OCM combined with WM could significantly relieve the cancer pain, improve the QOL, decrease the primary time of pain, prolong the analgesic duration time, reduce the dosage of analgesics and side events. The evidence levels were low or very low. [ABSTRACT FROM AUTHOR]

: Copyright of Chinese Journal of Integrative Medicine is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Xiong, Shao-quan, Chen, Yu, Wang, Li-juan, Lyu, Pan-pan, Liao, Wan, Wang, Cui, Ke, Jian-long, Zhu, Xi, Wang, Jin-yang, Shen, Xian-ying, Li, Guang-ping, Lin, Li-zhu

المصدر: Chinese Journal of Integrative Medicine; Jul2021, Vol. 27 Issue 7, p502-508, 7p

مصطلحات موضوعية: DRUG efficacy, HERBAL medicine, CANCER patients, SURVEYS, QUESTIONNAIRES, DESCRIPTIVE statistics, QUALITY of life, GENETIC techniques, CHINESE medicine, EDUCATIONAL attainment, DOSAGE forms of drugs, THERAPEUTICS

مصطلحات جغرافية: CHINA

مستخلص: Objective: To study the use of Chinese medicine (CM) in cancer patients in southern China. Methods: A total of 1,950 cancer patients finished questionnaires in four provinces in southern China. The survey included socio-demographic and clinical characteristics of participants, dosage forms, efficacy, and side effects. Results: The study results showed that cancer patients with higher education (>12 years) were more likely to accept the treatment of Chinese herbs. There were 54.61% (1,065 cases) of patients chose Chinese herbs for the initial treatment and 14.46% (282 cases) chose Chinese herbs as monotherapy. Most patients (54.51%, 1,063 cases) continuously used CM for more than 6 months, and a few of them (212 cases) used CM for up to 3 years. All kinds of dosage forms of CM had been used, including CM decoction, CM patent prescription and CM injection. Concerning the efficacy in the view of patients, 40.31% (786 cases) believed that it would be effective to take Chinese herbs before they starting the anti-cancer treatment, and the percentage increased to 81.08% after 1-month CM treatment. The effect of Chinese herbs was mainly demonstrated by symptom relief and improvement of quality of life, and 8.31% (162 cases) of patients experienced control of tumor growth and decreased tumor markers. Furthermore, only 14.31% (279 cases) participants reported that they experienced side effects during CM treatment. Conclusion: This large scale investigation reflects the current situation of domestic CM usage objectively and comprehensively, which might provide new ways for cancer treatment. [ABSTRACT FROM AUTHOR]

: Copyright of Chinese Journal of Integrative Medicine is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Xu, Xiao-qing, Deng, Wen-qi, Wang, Da-yang, Li, Meng, Kou, Dong-lei, Zhang, Pei-tong

المصدر: Chinese Journal of Integrative Medicine; Jul2021, Vol. 27 Issue 7, p496-501, 6p

مصطلحات موضوعية: THERAPEUTIC use of antineoplastic agents, SURVIVAL, DISEASE progression, RESEARCH, HERBAL medicine, CLINICAL trials, LIVER tumors, SMALL cell carcinoma, METASTASIS, TREATMENT duration, CANCER patients, BRAIN tumors, QUALITY of life, DESCRIPTIVE statistics, BONE metastasis, CHINESE medicine, LONGITUDINAL method, THERAPEUTICS

مستخلص: Objective: To evaluate the effect of Chinese medicine (CM) treatment on survival time and quality of life (QOL) in patients with small cell lung cancer (SCLC). Methods: This was an exploratory and prospective clinical observation. Patients diagnosed with SCLC receiving CM treatment were included and followed up every 3 months. The primary outcome was overall survival (OS), and the secondary outcomes were progression-free survival (PFS) and QOL. Results: A total of 136 patients including 65 limited-stage SCLC (LS-SCLC) patients and 71 extensive-stage SCLC (ES-SCLC) patients were analyzed. The median OS of ES-SCLC patients was 17.27 months, and the median OS of LS-SCLC was 40.07 months. The survival time was 16.27 months for SCLC patients with brain metastasis, 9.83 months for liver metastasis, 13.43 months for bone metastasis, and 18.13 months for lung metastasis. Advanced age, pleural fluid, liver and brain metastasis were risk factors, while longer CM treatment duration was a protective factor. QOL assessment indicated that after 6 months of CM treatment, scores increased in function domains and decreased in symptom domains. Conclusion: CM treatment might help prolong OS of SCLC patients. Moreover, CM treatment brought the trend of symptom amelioration and QOL improvement. These results provide preliminary evidence for applying CM in SCLC multi-disciplinary treatment. [ABSTRACT FROM AUTHOR]

: Copyright of Chinese Journal of Integrative Medicine is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)